21 results for «106»
21 results
Transcatheter options for degenerated surgical aortic valves - LIVE case
Recommended by PCR
08 Feb 2025 – From PCR Tokyo Valves 2025
A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.
A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

Transcatheter management of failed THV - LIVE case
Recommended by PCR
09 Feb 2025 – From PCR Tokyo Valves 2025
An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

Advanced mitral TEER - LIVE case
Recommended by PCR
24 Nov 2024 – From PCR London Valves 2024
Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:
- A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...

Transcatheter tricuspid valve replacement - LIVE case
Recommended by PCR
15 May 2024 – From EuroPCR 2024
An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

Imaging-guided left main PCI - LIVE case
Recommended by PCR
17 May 2024 – From EuroPCR 2024
A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

A stuck Rota burr in a "flintstone" coronary artery
18 Dec 2023
Step by Step video on how to deal with a stuck Rota burr with the same arterial access. Nice example of Kokeshi phenomenon.

Author

Author

FAME 3: A Randomized Trial of FFR-Guided Stenting Compared With CABG
12 Nov 2021
Examination of the study methodology and results according to the PICOT principle, SWOT analysis and real-world applicability of the FAME 3 trial presented at TCT 2021.

20 years of TAVI - Revolutionising medicine since 2002
18 May 2022
Twenty years ago, surgical aortic valve replacement (SAVR) was the only real option for patients with symptomatic aortic stenosis, and if the patient was considered at high operative risk, alternatives were very limited.

Author

Author

Author

Author

FIRE1 raises $25M to revolutionize heart failure home monitoring
15 Mar 2023

30 years of primary PCI – a tale of perseverance
16 May 2023
Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.

TRIGISTRY: Benefit of isolated surgical valve repair or replacement for functional tricuspid regurgitation and long-term outcomes stratified by the TRI-SCORE
31 Aug 2024
Alex Sticchi provides his take on the TRIGISTRY study presented by Julien Dreyfus at the ESC Congress 2024 in London.
Simultaneous publication in European Heart Journal, ehae578

Author

EuroPCR 2025: Late-breaking data demonstrate sustained significantly lower event rates with Elixir Medical’s DynamX® Bioadaptor over drug-eluting stent through three Years
21 May 2025

Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3
02 Apr 2025
Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.

Author

Shockwave Medical study confirms benefit of IVL-first strategy in real-world female patients with complex calcified lesions in late-breaking data presentation at EuroPCR 2025
20 May 2025

TRILUMINATE pivotal: A landmark randomized clinical trial of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation
04 Mar 2023
Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).

Author

Author

Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.

Author

TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome
03 Sep 2025
Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

Author

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!
17 Oct 2020
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.

Author

Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)
30 Oct 2024
Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.

Author

Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease: the FLAVOUR II trial
29 Mar 2025
Ali Nazmi Calik provides his take on the FLAVOUR II trial presented by Jian-An Wang at ACC.25 in Chicago.

Author
